F16.250
Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 code F16.250 refers to a condition where an individual is dependent on hallucinogens and experiences a hallucinogen-induced psychotic disorder characterized by delusions. This condition involves both a reliance on hallucinogenic substances and a severe mental health impact, including distortions in perception and beliefs. Understanding this diagnosis is important for recognizing its symptoms, causes, and available approaches to management.
Causes & Symptoms
Clinical Causes: Prolonged or frequent use of hallucinogenic substances such as LSD, psilocybin, or peyote Genetic predisposition to substance dependence or mental health disorders History of mental health issues that may be exacerbated by hallucinogen use Psychosocial factors, including stress, trauma, or environmental influences that encourage substance use
Key Symptoms: Persistent craving or need to use hallucinogens Loss of control over use despite negative consequences Development of psychotic symptoms such as hallucinations or paranoid delusions Delusions involving beliefs that are not based in reality, often related to paranoia or grandiosity Distorted perceptions of reality, including visual or auditory hallucinations Changes in mood, including anxiety, agitation, or depression Impaired social or occupational functioning Physical signs of substance use, such as dilated pupils, trembling, or sweating
Diagnostic & Treatment
Diagnosis Path: Diagnosis is made through a comprehensive clinical assessment including detailed history of substance use, mental health evaluation, and assessment for symptoms of psychosis. Healthcare providers may use standardized screening tools and blood or urine tests to confirm hallucinogen use. The clinician will evaluate the duration, frequency, and impact of both dependence and psychotic symptoms to establish the diagnosis according to ICD-10 criteria.
Treatment Protocols: Treatment strategies often involve a combination of approaches tailored to the individual's needs, including: - **Detoxification:** Supervised management to safely discontinue hallucinogen use - **Psychotherapy:** Cognitive-behavioral therapy (CBT), motivational interviewing, and supportive counseling to address dependence and psychotic symptoms - **Medication:** Antipsychotic medications, if indicated, to manage delusions or hallucinations, and medications to support mental health stability - **Rehabilitation:** Support groups and community-based services to foster recovery and prevent relapse - **Monitoring:** Regular follow-up to assess mental health improvement and prevent complications
Clinical Advice & FAQs
Billing Guidance
Is F16.250 a billable ICD-10 code?
Yes, F16.250 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.250?
Clinical documentation must specify the nature of Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions and any associated comorbidities for accurate reporting.
Cite this Clinical Reference